ImmuPharma plc (LON:IMM – Get Free Report) shares traded up 95.8% during mid-day trading on Thursday . The stock traded as high as GBX 2.49 ($0.03) and last traded at GBX 2.35 ($0.03). 42,281,480 shares traded hands during trading, an increase of 431% from the average session volume of 7,956,301 shares. The stock had previously closed at GBX 1.20 ($0.01).
ImmuPharma Stock Up 108.3 %
The firm has a 50 day moving average of GBX 1.36 and a two-hundred day moving average of GBX 1.63. The firm has a market capitalization of £10.41 million, a price-to-earnings ratio of -250.00 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Featured Articles
- Five stocks we like better than ImmuPharma
- Stock Dividend Cuts Happen Are You Ready?
- NVIDIA Deal Ignites Aurora Stock’s Explosive Potential
- The 3 Best Fintech Stocks to Buy Now
- Why AMD Stock Might Already Be This Year’s Best Buy
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- 3 Promising Penny Stocks to Watch for Long-Term Gains in 2025
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
